Twenty-four quinoxaline derivatives were evaluated for their antimycobacterial activity using BacTiter-Glo microbial cell viability assay. Moreover, they exhibited intracellular activity in infected macrophages, considering log-reduction and cellular viability. In addition, compounds 16 and 21 were potent against non-replicating M. Tb. and compound 21 was bactericidal. Therefore, quinoxaline derivatives could be considered for making further advances in the future development of antimycobacterial agents.
Tuberculosis (TB) is a chronic infection caused by Mycobacterium tuberculosis (M.
Tb.), which is the second cause of death from a single infectious agent. Due to its high infectivity it is estimated that a third of the world population is a reservoir of
Mycobacterium.
In 2000, within the Millennium Development Goals (MDG6), the United Nations proposed to halt the spread and reverse the incidence of TB by 2015. Some of these objectives have already been achieved. The TB mortality rate has decreased 45% since 1990 and more people have access to effective treatments and to early and sensitive diagnostic methods. However, epidemiological data are still alarming 1 These data indicate the urgent need to continue working in the development of new compounds against new targets and with new mechanisms of action for treating MDR-TB. It is also important to shorten the long periods of treatment because they are a common reason for treatment discontinuation on the part of the patient, and stopping the treatment too early is related with the appearance of resistant strains 3 . With this aim, our group has been working for several years on the synthesis and biological evaluation of new structures derived from quinoxalines. Quinoxaline derivatives show very interesting biological properties. Several studies have been published which justify the interest in these derivatives as antibacterial agents. As a result of our antituberculosis research project, several papers have been published in which both synthesis and biological activity assessments have been described for a large number of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives with a variety of substituents. Some of them have shown growth inhibition values of 99% and 100% [4] [5] [6] [7] [8] [9] .
This indicates that these types of structures are very interesting for developing new anti-TB molecules. Furthermore, it has been reported that oxidation of the nitrogen in the quinoxaline ring provides a significant increase in the antibacterial biological activity. 10 It has also been reported that the quinoxaline 1,4-di-N-oxide derivatives suffer a bioreduction process under hypoxic conditions 11 . This behavior could be interesting because in the caseous core of the tuberculous granulomas there is a low concentration of oxygen where non-replicating persistence (NRP) forms of M. Tb.
bacilli can survive 12 . These forms are thought to be the reason behind the need for long treatments and the development of tolerance to the treatment 13 .
Chalcones are precursors of flavonoids and isoflavonoids, which consist in two The starting benzofuroxans, were commercially available or were obtained by previously described methods 18 . The synthesis of quinoxaline 1,4-di-N-oxide intermediates were carried out by a variation of the Beirut reaction following the procedure described in the literature [19] [20] [21] .
The 10 novel chalcone analogs (1-10) were prepared by Claisen-Schmidt condensation 22 .
Benzaldehyde The structure and anti-tuberculosis activity data of the 24 compounds are shown in With regard to R 3 position, it seems to be less important for the anti-mycobacterial activity.
With regard to N-oxide groups of the quinoxaline ring, these groups seem to be essential for the activity as we can see comparing compounds 15 vs 16. This important loss of activity confirmed again that the presence of the both N-oxide groups is a structural requirement for biological activity 24, 25 .
According These results suggest that all compounds were active against RIF, INH and OFXresistant M. Tb. strains. Therefore, there is no cross-resistance with the antitubercular drugs used in the assay, supporting the idea that our compounds act through a different mechanism of action. These results are promising for the development of new effective compounds against the growing number of drug-resistant strains.
A compound is considered as bactericidal if the ratio MBC/MIC is ≤ 4 26 . This is important because bactericidal drugs can potentially shorten the standard treatment regimen, which is a minimum of 6 months for tuberculosis. Therefore and according to the results showed in Table 3 , compound 21 could be considered as bactericidal due to the low ratio obtained. If a compound lacks bactericidal activity, many times the colony-forming units (CFUs) are too numerous to count (TNTC) as observed with compound 16 27 . It is well known that quinoxaline 1,4-di-N-oxide possess a selective toxicity against hypoxic tumoral cells through a bioreductive activation process 28 . In the case of tuberculosis, the granulomatous lesions formed in the infected lungs present a hypoxic environment where TB bacilli are in a latent state of low metabolic activity. These nonreplicating persistence (NRP) M. Tb. bacilli is thought to be a main factor responsible for the long treatment periods and the emergence of antimicrobial tolerance 29 . Therefore, special attention should be paid to the NRP state of M. Tb. from the early stages of the drug discovery process. Therefore, the LORA assay, conducted under low oxygen conditions, has been included in the biological evaluation with the aim of identifying compounds able to acting on the non-replicative bacilli. As shown in Table 3 , compounds 16 and 21 were more potent against NPR M. Tb. being 8-fold and 4-fold more active under anaerobic conditions than aerobic conditions respectively. These results offer an important approach for studying this family of compounds in these conditions due to the important role that NRP M. Tb. bacilli play in influencing the duration of treatment.
M. Tb. can evade the immune response of macrophages and has the ability to reside inside them in a latent state. This evasion mechanism makes the effectiveness of treatment difficult and increases the microbial resistance 30, 31 .
With the aim of assessing the intracellular effectiveness of the 5 selected compounds in this infection phase, the activity in J774 infected macrophages was evaluated. All of the evaluated compounds showed high log-reduction in the burden of the intracellular bacilli (Table 4) . However, it was observed that none of the evaluated compounds showed dose response log-reduction in contrast to RIF.
At the lowest concentration, compounds 3 and 24 showed values > 2-log-reduction (> 99% inhibition) while compounds 16, 18 and 21 showed values > 1-log-reduction (> 90% inhibition). Therefore, the 5 evaluated compounds exhibited log-reduction among 3 to 4.5-fold more than RIF.
Compounds 16, 18 and 21 showed the highest log-reduction at the highest concentration and presented values of 26%, 65% and 47% of cellular viability respectively at this concentration. Therefore, compounds 18 and 21 stand out as being the most potent derivatives against intracellular bacilli, considering log-reduction and cell viability values. days post-infection.
b The three concentrations chosen were based on the MIC data generated in the HTS primary screen. The mid concentration bracketed the reported MIC with the lower concentration ten-fold below the mid and the higher concentration ten-fold above the mid.
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